European Commission Approves ELREXFIO (elranatamab-bcmm) for Relapsed/Refractory Multiple Myeloma (https://www.myeloma.org/european-commission-approves-elrexfio-elranatamab-bcmm-relapsedrefractory-multiple-myeloma)